Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stefano Rusconi

Showing results (171-180 of 192) with videos related to

Pageof 20
Sort By:
AIDS and Behavior|June 5, 2024
Assessing ChatGPT's Potential in HIV Prevention Communication: A Comprehensive Evaluation of Accuracy, Completeness, and InclusivityAndrea De Vito, Agnese Colpani, Giulia Moi, et al.
Antiviral Therapy|April 13, 2019
Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimenDaniele Armenia, Domenico Di Carlo, Alessandro Cozzi-Lepri, et al.
Plos One|November 19, 2013
Maraviroc as intensification strategy in HIV-1 positive patients with deficient immunological response: an Italian randomized clinical trialStefano Rusconi, Paola Vitiello, Fulvio Adorni, et al.
JCI Insight|November 16, 2021
PD-1 blockade counteracts post-COVID-19 immune abnormalities and stimulates the anti-SARS-CoV-2 immune responseCristian Loretelli, Ahmed Abdelsalam, Francesca D'Addio, et al.
AIDS Patient Care and Stds|September 15, 2021
Durability of Dolutegravir-Based Regimens: A 5-Year Prospective Observational StudyLucia Taramasso, Andrea De Vito, Elena Delfina Ricci, et al.
Viruses|July 29, 2023
Lipids and Transaminase in Antiretroviral-Treatment-Experienced People Living with HIV, Switching to a Doravirine-Based vs. a Rilpivirine-Based Regimen: Data from a Real-Life SettingPaolo Maggi, Elena Delfina Ricci, Canio Vito Martinelli, et al.
AIDS Research and Treatment|October 6, 2025
Lipids and Body Mass Index in Antiretroviral-Experienced People With HIV on Doravirine-Based Treatments: A Comparison Between Dual or Triple Regimen Versus Bictegravir-Based Triple RegimenPaolo Maggi, Addolorata Masiello, Barbara Menzaghi, et al.
Plos One|November 22, 2017
Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-week results of a randomized trialBarbara Rossetti, Roberta Gagliardini, Genny Meini, et al.
Diabetes Care|September 30, 2020
Sitagliptin Treatment at the Time of Hospitalization Was Associated With Reduced Mortality in Patients With Type 2 Diabetes and COVID-19: A Multicenter, Case-Control, Retrospective, Observational StudySebastiano Bruno Solerte, Francesca D'Addio, Roberto Trevisan, et al.
Diabetes|May 13, 2022
Immunogenicity and Safety of SARS-CoV-2 mRNA Vaccines in a Cohort of Patients With Type 1 DiabetesFrancesca D'Addio, Gianmarco Sabiu, Vera Usuelli, et al.
Pageof 20

Showing results (171-180 of 192) with videos related to

Sort By:
Pageof 20
AIDS and Behavior|June 5, 2024
Assessing ChatGPT's Potential in HIV Prevention Communication: A Comprehensive Evaluation of Accuracy, Completeness, and InclusivityAndrea De Vito, Agnese Colpani, Giulia Moi, et al.
Antiviral Therapy|April 13, 2019
Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimenDaniele Armenia, Domenico Di Carlo, Alessandro Cozzi-Lepri, et al.
Plos One|November 19, 2013
Maraviroc as intensification strategy in HIV-1 positive patients with deficient immunological response: an Italian randomized clinical trialStefano Rusconi, Paola Vitiello, Fulvio Adorni, et al.
JCI Insight|November 16, 2021
PD-1 blockade counteracts post-COVID-19 immune abnormalities and stimulates the anti-SARS-CoV-2 immune responseCristian Loretelli, Ahmed Abdelsalam, Francesca D'Addio, et al.
AIDS Patient Care and Stds|September 15, 2021
Durability of Dolutegravir-Based Regimens: A 5-Year Prospective Observational StudyLucia Taramasso, Andrea De Vito, Elena Delfina Ricci, et al.
Viruses|July 29, 2023
Lipids and Transaminase in Antiretroviral-Treatment-Experienced People Living with HIV, Switching to a Doravirine-Based vs. a Rilpivirine-Based Regimen: Data from a Real-Life SettingPaolo Maggi, Elena Delfina Ricci, Canio Vito Martinelli, et al.
AIDS Research and Treatment|October 6, 2025
Lipids and Body Mass Index in Antiretroviral-Experienced People With HIV on Doravirine-Based Treatments: A Comparison Between Dual or Triple Regimen Versus Bictegravir-Based Triple RegimenPaolo Maggi, Addolorata Masiello, Barbara Menzaghi, et al.
Plos One|November 22, 2017
Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-week results of a randomized trialBarbara Rossetti, Roberta Gagliardini, Genny Meini, et al.
Diabetes Care|September 30, 2020
Sitagliptin Treatment at the Time of Hospitalization Was Associated With Reduced Mortality in Patients With Type 2 Diabetes and COVID-19: A Multicenter, Case-Control, Retrospective, Observational StudySebastiano Bruno Solerte, Francesca D'Addio, Roberto Trevisan, et al.
Diabetes|May 13, 2022
Immunogenicity and Safety of SARS-CoV-2 mRNA Vaccines in a Cohort of Patients With Type 1 DiabetesFrancesca D'Addio, Gianmarco Sabiu, Vera Usuelli, et al.
Pageof 20